

Elisa Baldelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5405265/publications.pdf>

Version: 2024-02-01

16
papers

1,243
citations

933447

10
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

2513
citing authors

#	ARTICLE	IF	CITATIONS
1	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. <i>Cancer Discovery</i> , 2020, 10, 54-71.	9.4	820
2	Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 707-715.	1.1	160
3	Reverse Phase Protein Microarrays. <i>Methods in Molecular Biology</i> , 2017, 1606, 149-169.	0.9	55
4	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. <i>Molecular Cancer Research</i> , 2019, 17, 1815-1827.	3.4	40
5	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. <i>Proteomics - Clinical Applications</i> , 2015, 9, 928-937.	1.6	32
6	Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 198.	8.6	27
7	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. <i>Oncotarget</i> , 2015, 6, 32368-32379.	1.8	25
8	A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. <i>Molecular Oncology</i> , 2016, 10, 1585-1594.	4.6	21
9	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2021, 297, 101335.	3.4	14
10	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. <i>Cell Reports</i> , 2021, 37, 110060.	6.4	14
11	Kinase-driven metabolic signalling as a predictor of response to carboplatin+paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017, 117, 494-502.	6.4	10
12	The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow. <i>Clinical Proteomics</i> , 2020, 17, 9.	2.1	9
13	Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non-small cell lung cancer (NSCLC): a pilot study. <i>Oncotarget</i> , 2017, 8, 83343-83353.	1.8	6
14	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
15	Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas. <i>Genes</i> , 2021, 12, 1402.	2.4	3
16	Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2819.	4.1	1